Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203).
Michele Maio(University of Siena), Tibor Csőszi, Sulabha Ranganathan(Incyte (United States)), Sławomir Mańdziuk(Medical University of Lublin), Margarita Majem(Chinese Academy of Medical Sciences & Peking Union Medical College), Jacques Médioni, Gwénaëlle Gravis(Centre National de la Recherche Scientifique), Yubing Yao(Incyte (United States)), Mark Cornfeld(Incyte (United States)), Howard Yeh(Hospital de Santa Maria), Michael Schenker(Sorbonne Université)
Cited by 7
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k